AstraZeneca ( (AZN) ) is experiencing volatility. Read on for a possible explanation for the stock’s unusual movement.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
AstraZeneca’s stock is experiencing an upward movement due to promising developments in their clinical studies. The initiation of a study on surovatamig for rheumatoid arthritis and lupus, along with the completion of the Tezepelumab PRO Study for asthma control, are creating optimism among investors. Furthermore, the acceptance of a supplemental biologics license application for Enhertu in breast cancer treatment is bolstering market confidence, leading to a positive outlook for the company’s stock.
More about AstraZeneca
YTD Price Performance: 19.54%
Average Trading Volume: 4,464,186
Technical Sentiment Signal: Strong Buy
Current Market Cap: $231.1B
For further insights into AZN stock on TipRanks’ Stock Analysis page.
See more of today’s top stock gainers and losers.